Oncology Corporate Profile
Mologen AG is a biotechnology company specializing in the research and clinical development of innovative drugs in the fields of oncology and infectious diseases. Their most important developments to date are the DNA immunomodulator MGN1703, which they are currently subjecting to clinical trials in the treatment of advanced colorectal cancer and advanced lung cancer (non-small-cell lung cancer). And their cell-based cancer therapy MGN1601 for the treatment of advanced renal cancer (renal cell carcinoma), which is also a highly promising product, is currently undergoing clinical development as well.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|MGN1703||immunomodulator||Small Cell Lung Cancer (SCLC)||II|
|MGN1601||immunomodulator||Renal cell carcinoma (RCC)||I|
|MGN1703||immunomodulator||Various cancer types||I|
View additional information on product candidates here »